[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@AbbVieUSOncMed Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1785659011175473153.png) @AbbVieUSOncMed AbbVie Oncology Medical Affairs

AbbVie Oncology Medical Affairs posts on X about $abbv, rr the most. They currently have XXX followers and XX posts still getting attention that total XX engagements in the last XX hours.

### Engagements: XX [#](/creator/twitter::1785659011175473153/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1785659011175473153/c:line/m:interactions.svg)

- X Month XXX +116%
- X Months XXXXX -XX%
- X Year XXXXX -XX%

### Mentions: XX [#](/creator/twitter::1785659011175473153/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1785659011175473153/c:line/m:posts_active.svg)


### Followers: XXX [#](/creator/twitter::1785659011175473153/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1785659011175473153/c:line/m:followers.svg)

- X Month XXX +2.90%
- X Months XXX +16%
- X Year XXX +55%

### CreatorRank: undefined [#](/creator/twitter::1785659011175473153/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1785659011175473153/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks) 

**Social topic influence**
[$abbv](/topic/$abbv) #34, [rr](/topic/rr) #241

**Top accounts mentioned or mentioned by**
[@abbvie](/creator/undefined) [@drjulievose](/creator/undefined) [@yhkarimi](/creator/undefined) [@ashhematology](/creator/undefined) [@myelomatips](/creator/undefined) [@plasmacellpete](/creator/undefined) [@genmab](/creator/undefined) [@joshuabrodymd](/creator/undefined) [@pconnorjohnson](/creator/undefined) [@biostatgirl](/creator/undefined) [@paolaghionemd](/creator/undefined) [@majorajay](/creator/undefined) [@paolocaimimd](/creator/undefined) [@drraulcordoba](/creator/undefined) [@alankerrmd](/creator/undefined) [@societyofhemonc](/creator/undefined) [@cthieblemont](/creator/undefined) [@danilovlab](/creator/undefined) [@tobyeyre82](/creator/undefined) [@calliecoombsmd](/creator/undefined)

**Top assets mentioned**
[AbbVie Inc (ABBV)](/topic/$abbv)
### Top Social Posts
Top posts by engagements in the last XX hours

"Join @AbbVie during #ASH2025 for a poster on the real-world treatment landscape and outcomes of patients with BPDCN. #leusm #BPDCN Read more:"  
[X Link](https://x.com/AbbVieUSOncMed/status/1997681251864793433)  2025-12-07T14:55Z XXX followers, XXX engagements


"See updated @Abbvie data in #NSCLC at #NACLC2025 poster session held by @IASLC on Saturday December 6th 2025 #LungCancer #LCSM #NSCLC Abstract PP01.37 Post-hoc analysis of treatment-related adverse reactions with an ADC in NSCLC See abstracts here:"  
[X Link](https://x.com/AbbVieUSOncMed/status/1996692175313383728)  2025-12-04T21:24Z XXX followers, XXX engagements


"Join us to see updated @AbbVie data in #DLBCL at #ASH2025 @ASH_hematology #lymsm #lymphoma #hematology Abstract 1959: Outpatient administration in R/R DLBCL by Dr. Adelba Torres @rakv2000 et al. Abstract 1955: 3-year follow-up in 1L DLBCL by Dr. Lorenzo Falchi et al"  
[X Link](https://x.com/AbbVieUSOncMed/status/1997023628916076860)  2025-12-05T19:21Z XXX followers, XXX engagements


"Here at @AbbVie we remain committed to advancing oncology research and are proud to share XX abstracts including X oral presentations and XX posters across multiple disease states at #ASH25. Visit AbbVies booth # XXX and find our abstracts here:"  
[X Link](https://x.com/AbbVieUSOncMed/status/1997274829825728841)  2025-12-06T12:00Z XXX followers, XX engagements


"Join us for new and updated @AbbVie #FL data at #ASH2025 Oral 465: 3-year follow-up in 1L FL @LoriLeslieMD @JoshuaBrodyMD @ab_pau et al. Oral 466: First Disclosure of Phase X results in R/R FL by Dr Lorenzo Falchi @anetoc @anitiju0312 @c_thieblemont @Pavlovsky_Mig et al"  
[X Link](https://x.com/AbbVieUSOncMed/status/1997382189202170212)  2025-12-06T19:06Z XXX followers, XXX engagements


"Join us at #ASH25 as @AbbVie presents multiple scientific updates in #MultipleMyeloma research and development"  
[X Link](https://x.com/AbbVieUSOncMed/status/1997412462564421769)  2025-12-06T21:06Z XXX followers, XX engagements


"At #ASH25 results are presented by Dr. Raj Chakraborty @rajshekharucms on phase 1/2 dose escalation and expansion of B-Cell Maturation Antigen x CD3 Bispecific Antibody in patients with relapsed or refractory light chain amyloidosis"  
[X Link](https://x.com/AbbVieUSOncMed/status/1997769332475236447)  2025-12-07T20:45Z XXX followers, XXX engagements


"Join us and listen in on @AbbVie data at #ASH2025 @ASH_hematology #lymsm #leukemia #hematology Oral 1015: CD3xCD20 bispecific antibody-based regimens in pts with RT by Dr. Philip Thompson et al. Oral 1017: 2-year follow-up in pts with RT by Dr. Arnon Kater et al"  
[X Link](https://x.com/AbbVieUSOncMed/status/1997785008207974424)  2025-12-07T21:47Z XXX followers, XX engagements


"Join us to see updated @AbbVie data in #DLBCL at #ASH2025 @ASH_hematology #lymsm #lymphoma #hematology Abstract 5513: 4-year follow-up in R/R LBCL by @Yhkarimi @chanyooncheah @DrJulieVose et al. You can find this scientific abstract here:"  
[X Link](https://x.com/AbbVieUSOncMed/status/1997785497880453500)  2025-12-07T21:49Z XXX followers, XXX engagements


"Join us to see new @AbbVie PRO data in #FL at #ASH2025 @ASH_hematology #lymsm #lymphoma #hematology #FollicularLymphoma Abstract 5370: HRQoL in pts with R/R FL by Prof Kim Linton @c_thieblemont et al. You can find this scientific abstract here:"  
[X Link](https://x.com/AbbVieUSOncMed/status/1997785728294498479)  2025-12-07T21:50Z XXX followers, XXX engagements


"Join us at #ASH25 as @AbbVie presents scientific updates in #MultipleMyeloma research and development. Abstracts can be found at the #ASH25 abstract site:"  
[X Link](https://x.com/AbbVieUSOncMed/status/1998150603131031968)  2025-12-08T22:00Z XXX followers, XX engagements